TargetBeta
peptide deformylase, mitochondrial
2 programs in company-led studies act on PDF, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| visugromabrule | CatalYm | phase 3 | 65 running | GDF15 | NCIt |
| rilogrotugrule | LG Chem | phase 3 | 31 running | GDF15 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Cachexia, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Urinary Bladder Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 30, 2028visugromab · CatalYm · phase 3 · NCT04725474
- Mar 2030rilogrotug · LG Chem · phase 3 · NCT07888075
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.